CN112930175A - 治疗癫痫的方法 - Google Patents

治疗癫痫的方法 Download PDF

Info

Publication number
CN112930175A
CN112930175A CN201980049623.9A CN201980049623A CN112930175A CN 112930175 A CN112930175 A CN 112930175A CN 201980049623 A CN201980049623 A CN 201980049623A CN 112930175 A CN112930175 A CN 112930175A
Authority
CN
China
Prior art keywords
compound
fenfluramine
epilepsy
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980049623.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·P·贝查德
R·P·谢林顿
J-J·A·卡迪厄
P·K·塔里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zenong Pharmaceutical Co
Xenon Pharmaceuticals Inc
Original Assignee
Zenong Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenong Pharmaceutical Co filed Critical Zenong Pharmaceutical Co
Publication of CN112930175A publication Critical patent/CN112930175A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980049623.9A 2018-07-27 2019-07-26 治疗癫痫的方法 Pending CN112930175A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862711051P 2018-07-27 2018-07-27
US62/711,051 2018-07-27
PCT/US2019/043765 WO2020023923A1 (en) 2018-07-27 2019-07-26 Method for treating epilepsy

Publications (1)

Publication Number Publication Date
CN112930175A true CN112930175A (zh) 2021-06-08

Family

ID=67551433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980049623.9A Pending CN112930175A (zh) 2018-07-27 2019-07-26 治疗癫痫的方法

Country Status (20)

Country Link
US (1) US20200030260A1 (enExample)
EP (1) EP3829558B1 (enExample)
JP (1) JP2021530541A (enExample)
KR (1) KR20210061332A (enExample)
CN (1) CN112930175A (enExample)
AU (1) AU2019310600A1 (enExample)
BR (1) BR112021001135A2 (enExample)
CA (1) CA3106031A1 (enExample)
CL (1) CL2021000196A1 (enExample)
CO (1) CO2021002087A2 (enExample)
CR (1) CR20210095A (enExample)
EA (1) EA202190369A1 (enExample)
ES (1) ES2988130T3 (enExample)
IL (1) IL280128A (enExample)
MA (1) MA53329A (enExample)
MX (1) MX2021000987A (enExample)
PE (1) PE20211065A1 (enExample)
PH (1) PH12021550176A1 (enExample)
SG (1) SG11202100682YA (enExample)
WO (1) WO2020023923A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638898A (zh) * 2018-08-31 2021-04-09 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
SG11201804811WA (en) 2015-12-22 2018-07-30 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
KR20180095674A (ko) 2015-12-22 2018-08-27 조게닉스 인터내셔널 리미티드 대사 저항성 펜플루라민 유사체 및 그 사용 방법
RU2746000C2 (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)
CN114127150A (zh) * 2019-07-18 2022-03-01 巴斯夫欧洲公司 脲基甲酸酯基分散剂
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20230078820A1 (en) * 2021-09-01 2023-03-16 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions
CN118873517A (zh) * 2024-07-05 2024-11-01 上海柯西医药科技发展有限公司 大麻二酚与5-ht2b受体激动剂的组合的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140329908A1 (en) * 2013-05-03 2014-11-06 Berten Ceulemens Method For The Treatment of Dravet Syndrome
JP2016216438A (ja) * 2015-05-15 2016-12-22 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
JP2017057188A (ja) * 2015-09-14 2017-03-23 ゾゲニクス インターナショナル リミテッド 特別な形態のてんかんの併用療法
CN107530326A (zh) * 2015-02-25 2018-01-02 加利福尼亚大学董事会 用于治疗病症的5ht激动剂
CN111201039A (zh) * 2017-09-29 2020-05-26 吉伟研究有限公司 大麻二酚与5-ht2b受体激动剂或安非他明的组合治疗癫痫的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (enExample) 1960-11-05
GB1175516A (en) 1966-04-15 1969-12-23 Science Union & Cie New Phenyl-Aminopropane Derivatives and Preparations Containing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
WO1995033455A1 (en) * 1994-06-03 1995-12-14 Elmaleh David R Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
JP2001524124A (ja) 1997-05-07 2001-11-27 ガレン（ケミカルズ）リミティド テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具
US6591909B1 (en) 2001-12-20 2003-07-15 Halliburton Energy Services, Inc. Whey protein retarder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140329908A1 (en) * 2013-05-03 2014-11-06 Berten Ceulemens Method For The Treatment of Dravet Syndrome
CN107530326A (zh) * 2015-02-25 2018-01-02 加利福尼亚大学董事会 用于治疗病症的5ht激动剂
JP2016216438A (ja) * 2015-05-15 2016-12-22 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
JP2017057188A (ja) * 2015-09-14 2017-03-23 ゾゲニクス インターナショナル リミテッド 特別な形態のてんかんの併用療法
CN111201039A (zh) * 2017-09-29 2020-05-26 吉伟研究有限公司 大麻二酚与5-ht2b受体激动剂或安非他明的组合治疗癫痫的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARTHENA MARTIN等: "663. An Examination of the Mechanism of Action of Fenfluramine in Dravet Syndrome: A Look beyond Serotonin", BIOLOGICAL PSYCHIATRY, vol. 81, pages 140 *
RICHARD B. ROTHMAN等: "Serotonin releasing agents Neurochemical, therapeutic and adverse effects", PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR, vol. 71, pages 825 - 836, XP055635022, DOI: 10.1016/S0091-3057(01)00669-4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638898A (zh) * 2018-08-31 2021-04-09 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途
CN112638898B (zh) * 2018-08-31 2024-04-09 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途

Also Published As

Publication number Publication date
WO2020023923A1 (en) 2020-01-30
CA3106031A1 (en) 2020-01-30
EA202190369A1 (ru) 2021-06-10
AU2019310600A1 (en) 2021-02-11
EP3829558C0 (en) 2024-07-03
MX2021000987A (es) 2021-06-15
CL2021000196A1 (es) 2021-12-31
CO2021002087A2 (es) 2021-04-30
CR20210095A (es) 2021-06-01
EP3829558B1 (en) 2024-07-03
ES2988130T3 (es) 2024-11-19
SG11202100682YA (en) 2021-02-25
JP2021530541A (ja) 2021-11-11
KR20210061332A (ko) 2021-05-27
IL280128A (en) 2021-03-01
MA53329A (fr) 2022-03-02
PE20211065A1 (es) 2021-06-09
EP3829558A1 (en) 2021-06-09
BR112021001135A2 (pt) 2021-04-20
US20200030260A1 (en) 2020-01-30
PH12021550176A1 (en) 2021-10-11

Similar Documents

Publication Publication Date Title
CN112930175A (zh) 治疗癫痫的方法
US20240335418A1 (en) Safer psychoactive compositions
JP6328428B2 (ja) 神経疾患の治療のための新しい組成物
KR20230066313A (ko) 정신 장애 또는 정신적 증강에 유리한 벤조푸란 조성물
US20180338988A1 (en) Compositions for treating neurological disorders
US20190083420A1 (en) Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
KR101754045B1 (ko) 항코넥신제로서의 플레카이니드의 용도 및 향정신 약물 효과를 증강시키는 방법
CA2822453A1 (en) Novel morphinans useful as analgesics
CN116209657A (zh) 用于精神障碍或增强的2-氨基茚满化合物
US20230373940A1 (en) Carboxylic diarylthiazepineamines and uses thereof
US9463187B2 (en) Methylphenidate derivatives and uses of them
JP2010533717A (ja) 覚醒を促進する方法
US20230365519A1 (en) Carboxylic diarylthiazepineamines and uses thereof
JP5749176B2 (ja) トリプル再取込み阻害剤及びそれらの使用方法
HK40045266A (en) Method for treating epilepsy
US20200368310A1 (en) Treatment with nmda receptor modulators
TW200534848A (en) 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders
JP2023505054A (ja) 処置方法
CA3235692A1 (en) Modified forms of ambroxol for therapeutic use
WO2024229096A1 (en) Modified forms of ambroxol for therapeutic use
WO2024182774A1 (en) Deuterated and fluorinated empathogens

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045266

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210608